Larger-scale evaluations have shown that FLT3 mutations are found in approximately 30% of de novo diagnosed AML cases and are divided between ITDs (about 25%) and point mutations in the TKD (7–10%) [51]. The gene discussed is FLT3; the disease is acute myeloid leukemia.